DOCSLIB.ORG

Returning Research Test Results: Know Your Ethical and Legal Obligations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Returning Research Test Results: Know Your Ethical and Legal Obligations Returning Research Test Results: Know Your Ethical and Legal Obligations © Association of Clinical Research Professionals ǀ acrpnet.org Returning Research Test Results: Know Your Ethical and Legal Obligations MICHELLE GRIENAUER, JD, MPH, CIP SENIOR REGULATORY ATTORNEY AT KINETIQ (A DIVISION OF QUORUM) © Association of Clinical Research Professionals ǀ acrpnet.org TITLE OF SECTION Disclosure The presenter(s) for today’s session: I have a relevant financial relationship with respect to this educational activity with the following organization: Employee of Kinetiq (a division of Quorum Review) © Association of Clinical Research Professionals ǀ acrpnet.org TITLE OF SECTION Learning Objectives Upon completion of this presentation, participants should be able to: • Describe the regulatory requirements and ethical implications related to returning research test results. • Recognize how the CLIA and HIPAA regulations may conflict regarding when an individual may receive research test reports and will be able to discuss potential solutions to resolve the conflict. • Develop approaches for IRBs handling requests to return test results that were generated in a non-CLIA- certified laboratory. © Association of Clinical Research Professionals ǀ acrpnet.org WHAT DO RESEARCH PARTICIPANTS WANT? SURVEY SAYS… 90% OF RESEARCH PARTICIPANTS WANT THEIR STUDY RESULTS!* Citation: *E.g., Matthew P. Kirschen,Agnieszka Jaworska, and Judy Illes, Subjects’Expectations in Neuroimaging Research, 23 Magnetic Resonance Imaging 205 (January 2006). OVERVIEW • Background • 2016 HIPAA • Ethical Issues Guidance • CLIA • FDA • HIPAA • Best Practices • 2014 Amendments to CLIA and HIPAA RETURNING STUDY RESULTS – A SPECTRUM • Return of Incidental Findings • Return of Individual Research Results • Return of Aggregate Study Results • Public Release of Study Data* Citation: *SACHRP Letter to the HHS Secretary, Attachment C: Return of Individual Results and Special Consideration of Issues Arising from Amendments of HIPAA and CLIA (July 22, 2015), http://www.hhs.gov/ohrp/sachrp/commsec/attachmentc:letter9/28/15.html . The Legal Question: The Ethical Question: Do the CLIA laboratory According to generally accepted requirements and the HIPAA ethical principles of research, Privacy Rule, allow or require should investigators provide research participants with investigators to provide their individual research test research participants with results? their individual research test results? ETHICAL ISSUES Research vs. Clinical Care • Therapeutic Misconception • Translational Research* Citation: *Susan M. Wolf, et al., Mapping the Ethics of Translational Genomics: Situating Return of Results and Navigating the Research-Clinical Divide, 43 J.L. Med. & Ethics 486 (October 2015); Presidential Commission for the Study of Bioethical Issues, Anticipate and Communicate: Ethical Management of Incidental and Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts (December 2013), http://bioethics.gov/node/316. ETHICAL ISSUES Researcher Duty to Participants • Respect for persons • Beneficence • Justice FACTORS TO CONSIDER When Deciding Whether to Return Research Test Results • Analytic and clinical validity • Clinical actionability • Clinical or reproductive significance • Magnitude of potential harm • Informed consent process • Applicable law* Citation: *Presidential Commission for the Study of Bioethical Issues, Anticipate and Communicate: Ethical Management of Inci- dental and Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts (December 2013), http://bioethics.gov/node/316; Susan M. Wolf et al., Managing Incidental Findings and Research Results in Genomic Research Involving Biobanks & Archived Datasets, 14 Genetics in Med. 361 (April 2012); Richard R. Fabsitz et al., Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants: Updated Guidelines from a National Heart, Lung and Blood Institute Working Group, 3 Circulation: Cardiovascular Genetics 574 (December 2010). APPLICABLE LAWS There is currently no federal law or regulation in the US that directly addresses the return of research results or incidental findings. HUMAN SUBJECT PROTECTION REGULATIONS The federal human subject protection regulations do not currently address the return of individual results to research subjects. Indirect implications: General requirements for informed consent. BUT the revised Common Rule includes new elements of informed consent. Depending on the type of research, a participant must be informed whetheror not they will receive clinically relevant research results, including individual research results. Citation: *45 C.F.R. §§ 46.116(a)(2), (a)(3), (b)(5) (2016); 21 C.F.R. §§ 50.25(a)(2), (a)(3), (b)(5) (2016); 82 Fed. Reg 7,149, 7,266 (Jan. 19, 2017). CLIA AND HIPAA The Clinical Laboratory Improvement Amendments of 1988 (CLIA) and Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule affect when a research participant may/must be provided with research test results. CLIA The Clinical Laboratory Improvement Amendments of 1988 (CLIA) Established to strengthen federal oversight of clinical laboratories and to ensure the accuracy and reliability of patient test results. “CLIA Certification” Facilities that meet the CLIA definition of a “laboratory” must obtain certification prior to conducting patient testing.* Citation: *CLIA Laboratory Requirements, 42 C.F.R. § 493 (2015). CLIA (CONT.) • CLIA-Exempt Laboratories* CLIA-certification is not required for laboratories in states with requirements equal to or more stringent than CLIA. • CLIAExceptions** CLIA does not apply to research laboratories that do not report patient specific results “for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of individual patients.” Citation: *42 C.F.R. § 493.3(b)(2016); **42 C.F.R. § 493.2(2016.) CLIA (CONT.) • Exemption vs. Exception • Research laboratories “excepted” from CLIA, not “exempt” from CLIA. Same difference?* Citation: *Mark Barnes et al., The CLIA/HIPAA Conundrum of Returning Test Results to Research Participants, 14 Bloomberg BNA Med. Res. L. & Pol. Rep. 491 (July 2015) PENALTIES FOR CLIA VIOLATIONS • Criminal Sanctions • Suspension of Medicare payments • For intentional violations - imprisonment(up to 1 year) or fine (up to $100,000) • Directed plan of correction • Civil Suit • State onsite monitoring* • CMA can bring suit to enjoin the operations of a noncompliant laboratory. • Civil Money Penalty • $50-$10,000 per day of noncompliance • Suspension, limitation, or revocation of a CLIA certificate Citation: *42 C.F.R. §§ 493.1800- 1850 (2016). HIPAA • The Health Insurance Portability andAccountability Act (HIPAA) Privacy Rule • Establishes standards for protecting the privacy of individually identifiable health information. • Confers rights on individuals, including the rights to access to all of the protected health information maintained in the individual’s “designated record set.” Citation: 45 C.F.R. § 160 (2016); 45 C.F.R. § 164, Subparts A and E (2016). DESIGNATED RECORD SET (DRS) • “Designated record set” – A group of records maintained by or for a covered entity thatis: • (i) The medical records and billing records about individuals maintained by or for a covered health care provider; • (ii) The enrollment, payment, claims adjudication, and case or medical management record systems maintained by or for a health plan; or • (iii) Used, in whole or in part, by or for the covered entity to make decisions about individuals. • “Record” means any item, collection, or grouping of information that includes protected health information and is maintained, collected, used, or disseminated by or for a coveredentity.* Citation: *45 C.F.R. § 164.501 (2016). PENALTIES FOR HIPAA VIOLATIONS • Criminal sanctions • Fine of $50,000-$250,000 and imprisonment for 1-10 years* • Civil money penalty • Range: $100 per violation, with an annual maximum of $25,000 for repeat violations, to $50,000 per violation, with an annual maximum of $1.5 million. • Exclusion from Medicare participation.** Citation: *42 U.S.C. § 1320d-6 (2016); **45 C.F.R. § 160, Subparts C, D, and E (2016); CLIA PROGRAM AND HIPAA PRIVACY RULE; PATIENTS’ ACCESS TO TEST REPORTS. • On Feb. 6, 2014, HHS promulgated a joint OCR/CMS rule.* • Amended both the CLIA Laboratory Requirements andthe HIPAA Privacy Rule. • HHS Intent: • Remove barriers to an individual’s direct access to his or her own test reports from laboratories. • Empower individuals to better manage their health and take action to prevent and control disease.* Citation: *CLIA Program and HIPAA Privacy Rule; Patients’ Access to Test Reports, 79 Fed. Reg. 7,290 (Feb. 6, 2014) (amending 42 C.F.R. § 493.1291; 45 C.F.R. § 164.524). CLIA Before After • CLIA-certified laboratories only • CLIA-certified laboratories may allowed to disclose laboratory give completed test results results to certain individuals (e.g. directly to a patient.* provider ordering test). • Depending on state law, a patient might not be authorized to order or receive a test result. Citation: *42 C.F.R. §§ 493.1291(f), (l) (2016). HIPAA Before After • Access provisions did not apply • Removed the exception. to CLIA-certified and CLIA- • Laboratories must allow an exempt laboratories. individual access to test results • Exceptions were originally that are part of the designated created to avoid conflict with record set.* CLIA, which restricted patient access to test reports.
Load more

Recommended publications
  • Returning Individual Research Results to Participants: Guidance for a New Research Paradigm
    THE NATIONAL ACADEMIES PRESS This PDF is available at http://nap.edu/25094 SHARE Returning Individual Research Results to Participants: Guidance for a New Research Paradigm DETAILS 380 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-47517-4 | DOI 10.17226/25094 CONTRIBUTORS GET THIS BOOK Jeffrey R. Botkin, Michelle Mancher, Emily R. Busta, and Autumn S. Downey, Editors; Committee on the Return of Individual-Specific Research Results Generated in Research Laboratories; Board on Health Sciences Policy; Health and FIND RELATED TITLES Medicine Division; National Academies of Sciences, Engineering, and Medicine Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. Returning Individual Research Results to Participants: Guidance for a New Research Paradigm Returning Individual Research Results to Participants: Guidance for a New Research Paradigm Jeffrey R. Botkin, Michelle Mancher, Emily R. Busta, and Autumn S. Downey, Editors Committee on the Return of Individual-Specific Research Results Generated
    [Show full text]
  • The Legal Risks of Returning Results of Genomics Research
    ©American College of Medical Genetics and Genomics SPECIAL ARTICLE The legal risks of returning results of genomics research Ellen Wright Clayton, MD, JD1 and Amy L. McGuire, JD, PhD2 Published guidelines suggest that research results and incidental research results. We caution against this and argue in this essay that findings should be offered to study participants under some circum- the debate to date has failed to give adequate weight to a number of stances. Although some have argued against the return of results in fundamental ethical and policy issues that should undergird policy research, many cite an emerging consensus that there is an ethical on return of research results in the first instance, many of which go to obligation to return at least some results; the debate quickly turns the fundamental differences between research and clinical care. We to issues of mechanics (e.g., which results? who discloses? for how confine our comments to research using data from large biobanks, long does the obligation exist?). Although commentators are careful the topic of the guidelines proposed in this symposium issue. to distinguish this as an ethical rather than legal obligation, we wor- ry that return of results may unjustifiably become standard of care Genet Med 2012:14(4):473–477 based on this growing “consensus,” which could quickly lead to a le- Key Words: biobanking; ethics; genetics; law; policy; return of results gal (negligence-based) duty to offer and return individualized genetic A number of things seem to occur in many meetings about the published guidelines are generally guarded, the rhetoric return of individual results obtained in research involv- at these meetings both for and against offer and disclosure ing genome-wide tests and large amounts of clinical data.
    [Show full text]
  • Meeting Minutes
    Association of Bioethics Program Directors Westin Pittsburgh Convention Center Hotel Rooms 304 and 305 Pittsburgh, PA October 23, 2019 Meeting Minutes Meeting started at 6:00 PM In Attendance Applewhite Megan Albany Medical College Bolton Jonathan University of New Mexico Bulger Jeffrey Chicago Medical School Case Gretchen University of Utah Demme Richard University of Rochester Derse Arthur MCW Doukas David Tulane University Eberl Jason St. Louis University Gallagher Colleen University of Texas Garrett-Bell Jamila Emory University (notetaker) Goodman Ken University of Miami Grady Christine NIH Clinical Center Hendriksen Joan Children’s Minnesota Hester Micah UAMS Iltis Ana Wake Forest University Joffe Steve U Penn Jones Nora Temple University Juengst Eric UNC Kaldjian Lauris University of Iowa King Nancy Wake Forest University Kinlaw Kathy Emory University Klitzman Robert Columbia University Koenig Barbara UCSF Kogan Claudio U. of Texas Rio Grande Valley SOM Krohmal Ben MedStar Washington Kuczewski Mark Loyola University Lee Sandra Columbia University Lipman Hannah Hackensack University Medical Center Macpherson Cheryl St. George's University McGuire Amy Baylor College of Medicine Meador Keith VUMC Mitchell Christine Harvard Nash Ryan Ohio State University Parker Lisa University of Pittsburgh Powderly Kathy SUNY Downstate Medical Center Redinger Michael Western Michigan University Rhodes Rosamund Icahn School of Med at Mt. Sinai Rosell Tarris Kansas City University Rosenthal M. Sara University of Kentucky Sederstrom Nneka Children's Minnesota Sharp Richard Mayo Clinic Solomon Mildred The Hastings Center Streiffer Robert University of Wisconsin, Madison Tabor Holly Stanford Center Wilfond Ben Seattle Children’s Wolpe Paul Emory University Wynia Matt University of Colorado Welcome and Introductions: Paul Root Wolpe Paul welcomed and thanked members for attending the meeting.
    [Show full text]
  • MRCT Center Return of Individual Results to Participants Toolkit, Version 1.0 (Accessed At
    MRCT Center Return of Individual Results to Participants Toolkit Framework Version 1.2 22 November 2017 Return of Individual Results Toolkit Table of Contents INTRODUCTION .............................................................................................................................................. 2 Figure 1: Clinical Trial Data Types That May be Returned ........................................................................ 3 Figure 2: Return of Individual Results Tasks and Tools by Trial Phase for Clinical Teams ......................... 4 1. TOOLS FOR THE TEAM PLANNING THE STUDY ....................................................................................... 5 Tool 1: Rationale Matrix for Returning Various Data Types ....................................................................... 5 Tool 2: Points to Consider Along the Clinical Trial Timeline ....................................................................... 9 Tool 3: Selected Return of Individual Results Regulations and Resources ............................................... 16 Return of Results implications Under HIPAA / CLIA ................................................................................. 18 Tool 4: Informed Consent Language for Return of Individual Results ...................................................... 20 2. TOOLS FOR INSTITUTIONAL REVIEW BOARDS/ETHICS COMMITTEES .................................................. 27 Tool 5: Checklist for Institutional Review Board (IRB) and Ethics Committees ......................................
    [Show full text]
  • Returning Individual Research Results to Participants: Guidance for a New Research Paradigm
    THE NATIONAL ACADEMIES PRESS This PDF is available at http://nap.edu/25094 SHARE Returning Individual Research Results to Participants: Guidance for a New Research Paradigm DETAILS 398 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-47517-4 | DOI 10.17226/25094 CONTRIBUTORS GET THIS BOOK Jeffrey R. Botkin, Michelle Mancher, Emily R. Busta, and Autumn S. Downey, Editors; Committee on the Return of Individual-Specific Research Results Generated in Research Laboratories; Board on Health Sciences Policy; Health and FIND RELATED TITLES Medicine Division; National Academies of Sciences, Engineering, and Medicine Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. Returning Individual Research Results to Participants: Guidance for a New Research Paradigm Summary1 Biospecimens from research participants are an essential resource for a broad range of studies, from exploratory, basic science inquiries to clinical trials using well-validated tests. These types of research have been enormously valuable in advancing knowledge about almost every aspect of human health and disease. The conduct of research with human volunteers is dependent on a collaborative, productive relationship between participants who give their time and samples and the investigators and research teams that conduct the research.
    [Show full text]
  • A Private Right of Action for Informed Consent in Research
    Chicago-Kent College of Law Scholarly Commons @ IIT Chicago-Kent College of Law All Faculty Scholarship Faculty Scholarship January 2015 A Private Right of Action for Informed Consent in Research Valerie Gutmann Koch IIT Chicago-Kent College of Law, [email protected] Follow this and additional works at: https://scholarship.kentlaw.iit.edu/fac_schol Part of the Health Law and Policy Commons Recommended Citation Valerie Gutmann Koch, A Private Right of Action for Informed Consent in Research, 45 Seton Hall L. Rev. 173 (2015). Available at: https://scholarship.kentlaw.iit.edu/fac_schol/826 This Article is brought to you for free and open access by the Faculty Scholarship at Scholarly Commons @ IIT Chicago-Kent College of Law. It has been accepted for inclusion in All Faculty Scholarship by an authorized administrator of Scholarly Commons @ IIT Chicago-Kent College of Law. For more information, please contact [email protected], [email protected]. KOCH(DO NOT DELETE) 1/15/2015 5:31 PM A Private Right of Action for Informed Consent in Research Valerie Gutmann Koch* INTRODUCTION ............................................................................ 174 I. A PRIVATE RIGHT OF ACTION FOR TREATMENT BUT NOT RESEARCH .......................................................................... 177 A. Informed Consent to Treatment ............................... 177 B. Informed Consent to Research .................................. 183 II. THE EVOLVING RESEARCH MODEL AND THE SHIFTING INVESTIGATOR-PARTICIPANT RELATIONSHIP ....................
    [Show full text]
  • Participant Satisfaction with a Preference-Setting Tool for The
    JREXXX10.1177/1556264615599620Journal of Empirical Research on Human Research EthicsHolm et al. 599620research-article2015 IRB Operations Journal of Empirical Research on Human Research Ethics Participant Satisfaction With a 2015, Vol. 10(4) 414 –426 © The Author(s) 2015 Reprints and permissions: Preference-Setting Tool for the Return sagepub.com/journalsPermissions.nav DOI: 10.1177/1556264615599620 of Individual Research Results in Pediatric jre.sagepub.com Genomic Research Ingrid A. Holm1,2, Brittany R. Iles3, Sonja I. Ziniel1,2, Phoebe L. Bacon4, Sarah K. Savage1, Kurt D. Christensen2, Elissa R. Weitzman1,2, Robert C. Green2,5, and Noelle L. Huntington1,2 Abstract The perceived benefit of return of individual research results (IRRs) in accordance to participants’ preferences in genomic biobank research is unclear. We developed an online preference-setting tool for return of IRRs based on the preventability and severity of a condition, which included an opt-out option for IRRs for mental illness, developmental disorders, childhood- onset degenerative conditions, and adult-onset conditions. Parents of patients <18 years of age at Boston Children’s Hospital were randomized to the hypothetical scenario that their child was enrolled in one of four biobanks with different policies for IRRs to receive (a) “None,” (b) “All,” (c) “Binary”—choice to receive all or none, and (d) “Granular”—use the preference-setting tool to choose categories of IRRs. Parents were given a hypothetical IRRs report for their child. The survey was sent to 11,391 parents and completed by 2,718. The Granular group was the most satisfied with the process, biobank, and hypothetical IRRs received.
    [Show full text]
  • The Ethical and Legal Framework for a Genomics England and Sano Genetics Participant Engagement Platform
    The ethical and legal framework for a Genomics England and Sano Genetics participant engagement platform england Authors Colin Mitchell, Tanya Brigden and Alison Hall April 2021 A PHG Foundation report on the ethical and legal framework for a Genomics England and Sano Genetics participant engagement platform developed with funding from Innovate UK’s Digital Health Technology Catalyst competition. Acknowledgements This report is funded through grant funding from Innovate UK Industry Strategy Challenge Fund, Digital Health Technology Catalyst Round 4: Collaborative R&D, grant number 105415. We thank Fiona Maleady-Crowe, Shahla Salehi and Christine Patch (from Genomics England), Patrick Short (Sano Genetics) and other members of the project team for their input. Declaration of interests Alison Hall is a member of the Ethics Advisory Committee of Genomics England. Disclaimer The following report is intended to provide general information and understanding of the law. It should not be considered legal advice, nor used as a substitute for seeking qualified legal advice. URLs in this report were correct as of March 2021 Written and produced by PHG Foundation 2 Worts Causeway, Cambridge, CB1 8RN, UK +44 (0)1223 761900 www.phgfoundation.org © 2021 PHG Foundation Correspondence to: [email protected] The PHG Foundation is a health policy think-tank and linked exempt charity of the University of Cambridge. We work to achieve better health through the responsible and evidence- based application of biomedical science. We are a registered company, no. 5823194. PHG Foundation 2021 The ethical and legal framework for a participant engagement platform Executive summary The development of digital technologies has greatly increased the potential for more active involvement by participants in large-scale, long-term health research.
    [Show full text]
  • Patient-Reported Outcomes Following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: a Systematic Review
    Journal of Personalized Medicine Review Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review Rachele M. Hendricks-Sturrup 1,2,* , Lucson Joseph 3 and Christine Y. Lu 1 1 Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA 02215, USA; [email protected] 2 Duke-Margolis Center for Health Policy, Duke University, Washington, DC 20004, USA 3 Tanner Health System, Carrollton, GA 30117, USA; [email protected] * Correspondence: [email protected] Abstract: Background: Patient-reported outcomes (PROs) and PRO measures (PROMs) are real-world evidence that can help capture patient experiences and perspectives regarding a clinical intervention such as genetic testing. Objective: To identify and capture methods and qualitative PRO themes among studies reporting PROs following genetic testing for FH, breast and ovarian cancer syndrome, and Lynch syndrome. Methods: A systematic review was conducted via PubMed/MEDLINE, EMBASE, and Yale University’s TRIP Medical Databases on articles published by April 2021. Results: We identified 24 studies published between 1996 and 2021 representing 4279 participants that reported PROs following genetic testing for FH, breast and ovarian cancer syndrome, and Lynch syndrome. Studies collected and reported PROs from validated PROM instruments (n = 12; 50%), validated Citation: Hendricks-Sturrup, R.M.; surveys (n = 7;
    [Show full text]
  • Return of Research Results from Genomic Biobanks: Cost Matters
    ©American College of Medical Genetics and Genomics COMMENTARY Return of research results from genomic biobanks: cost matters Marianna J. Bledsoe, MA1, Ellen Wright Clayton, MD, JD2, Amy L. McGuire, JD, PhD3, William E. Grizzle, MD, PhD4, P. Pearl O’Rourke, MD5 and Nikolajs Zeps BSc (Hons), PhD6,7 Return of individual research results (IRRs) to study partici- To illustrate the cost and practical implementation challenges, pants has been, and continues to be, hotly debated. The role it is useful to consider some examples. ClinSeq, which has been of biobanks in the return of research results had received little cited as an example demonstrating that return of research results attention until the recent publication from Susan Wolf et al.,1 from biobanks need not be prohibitively costly or difficult,3 is which presents a detailed discussion and 10 recommendations unique in a number of ways that limits its ­generalizability. The regarding the return of results from biobanks. The authors pro- purpose of ClinSeq (http://www.genome.gov/ClinSeq/) is to pose that if reidentification of an individual participant (whom pilot large-scale medical sequencing in a clinical research setting. they also call a “contributor”) is possible, the biobank, as the The researcher in this project has a direct, ongoing relationship central hub in a biobank research system, should enable the sys- with the participants/contributors, and one of the main aims of tem to (i) clarify the criteria for evaluating findings and develop the study is to explore issues around return of research results. a list of returnable findings; (ii) analyze a particular finding in The primary study includes return of research results, genetic relation to the aforementioned list/criteria; (iii) reidentify the counseling, and retesting in a Clinical Laboratory Improvement individual participant/contributor; and (iv) recontact them to Amendments–approved laboratory.
    [Show full text]
  • Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants
    Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Fabsitz, R., Richard, Mcguire, R., Amy, Sharp, M., Richard, Puggal, G., Mona, Beskow, Gonzalez, Laura, Biesecker, Wright, Leslie, Bookman, H., Ebony, Burke, V., Wylie, Burchard, M., Esteban, Church, P., George, Clayton, R., Ellen, Eckfeldt, Pearl, John, Fernandez, Lyman, Conrad, Fisher, D., Rebecca, Fullerton, R., Stephanie, Gabriel, K.F., Stacey, Gachupin, V., Francine, James, M., Cynthia, Jarvik, L., Gail, Kittles, L., Rick, Leib, L., Jennifer, Oʼdonnell, L., Christopher, Oʼrourke, L., P., Rodriguez, L., Laura, Schully, L., Sheri, Shuldiner, L., Alan, Sze, L., Rebecca, Thakuria, L., Joseph, Wolf, L., Susan, and Burke, L., Gregory. 2010. Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants: Updated Guidelines From a National Heart, Lung, and Blood Institute Working Group." Circulation: Cardiovascular Genetics 3, no. 6: 574-80. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:42667837 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#OAP NIH Public Access Author Manuscript Circ Cardiovasc Genet. Author manuscript; available in PMC 2011 December 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Circ Cardiovasc Genet. 2010 December 1; 3(6): 574±580. doi:10.1161/CIRCGENETICS.110.958827.
    [Show full text]
  • Suggested Policy Points-To-Consider on the Return of Epigenetic
    Suggested Policy Points-to-Consider on the Return of Epigenetic Research Results The vast majority of current IHEC projects are fundamental epigenome mapping studies that are unlikely to reveal clinically valid and actionable health information that might be of interest to research participants, and in which the identities of participants have been irrevocably removed from research datasets, thus precluding recontact of participants. However, as epigenetics continues to progress and leads to insights into health and disease, the return of individual epigenetic research results to research participants will be of growing importance. This Points-to-Consider document therefore aims to provide forward- looking general guidance, based on the findings of the International Human Epigenome Consortium (IHEC) Bioethics Workgroup Subgroup on the return of results in epigenomic research (“The Subgroup”). Incidental findings, as well as individual findings directly related to the topic of research, may arise during the course of a research project; these Points-to-Consider apply to both types of findings (referred to here as research results), but only if they are epigenetic findings. In particular, epigenetic disease-linked data may have germline or somatic genetic sequence or variation as its source and, in this case, researchers should refer to guidance on the return of results in genomics for such results.1 The Subgroup recognizes that cultural, ethical and legal considerations on the return of research results vary between countries and geographic regions. In consideration of this variance, the Points-to-Consider outlined below should be considered as non-binding guidelines provided to assist projects in establishing their own policies on the return of research results to adult research participants.
    [Show full text]